JP7426940B2 - 心血管リスクを低減するためのpcsk9阻害剤の使用 - Google Patents

心血管リスクを低減するためのpcsk9阻害剤の使用 Download PDF

Info

Publication number
JP7426940B2
JP7426940B2 JP2020546481A JP2020546481A JP7426940B2 JP 7426940 B2 JP7426940 B2 JP 7426940B2 JP 2020546481 A JP2020546481 A JP 2020546481A JP 2020546481 A JP2020546481 A JP 2020546481A JP 7426940 B2 JP7426940 B2 JP 7426940B2
Authority
JP
Japan
Prior art keywords
patient
patients
risk
alirocumab
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020546481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515772A5 (cg-RX-API-DMAC7.html
JP2021515772A (ja
Inventor
ローレンス・ベサック
コリンヌ・アノタン
ロバート・ポーディー
ウィリアム・サシーラ
グレゴリー・シュウォルツ
フィリップ・シュテグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021515772A publication Critical patent/JP2021515772A/ja
Publication of JP2021515772A5 publication Critical patent/JP2021515772A5/ja
Priority to JP2023207363A priority Critical patent/JP2024028919A/ja
Application granted granted Critical
Publication of JP7426940B2 publication Critical patent/JP7426940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020546481A 2018-03-06 2019-03-06 心血管リスクを低減するためのpcsk9阻害剤の使用 Active JP7426940B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023207363A JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201862639407P 2018-03-06 2018-03-06
US62/639,407 2018-03-06
US201862640361P 2018-03-08 2018-03-08
US62/640,361 2018-03-08
US201862641082P 2018-03-09 2018-03-09
US62/641,082 2018-03-09
US201862641918P 2018-03-12 2018-03-12
US62/641,918 2018-03-12
US201862657495P 2018-04-13 2018-04-13
US62/657,495 2018-04-13
US201862683695P 2018-06-12 2018-06-12
US62/683,695 2018-06-12
US201862688622P 2018-06-22 2018-06-22
US62/688,622 2018-06-22
US201862717530P 2018-08-10 2018-08-10
US62/717,530 2018-08-10
US201862736284P 2018-09-25 2018-09-25
US62/736,284 2018-09-25
US201862744008P 2018-10-10 2018-10-10
US62/744,008 2018-10-10
US201862746319P 2018-10-16 2018-10-16
US62/746,319 2018-10-16
US201862770530P 2018-11-21 2018-11-21
US62/770,530 2018-11-21
US201862775219P 2018-12-04 2018-12-04
US62/775,219 2018-12-04
US201962797680P 2019-01-28 2019-01-28
US62/797,680 2019-01-28
US201962802545P 2019-02-07 2019-02-07
US62/802,545 2019-02-07
US201962806313P 2019-02-15 2019-02-15
US62/806,313 2019-02-15
EP19305247.9 2019-03-04
EP19305247 2019-03-04
PCT/US2019/021034 WO2019173530A1 (en) 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023207363A Division JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2021515772A JP2021515772A (ja) 2021-06-24
JP2021515772A5 JP2021515772A5 (cg-RX-API-DMAC7.html) 2022-03-10
JP7426940B2 true JP7426940B2 (ja) 2024-02-02

Family

ID=66001316

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546481A Active JP7426940B2 (ja) 2018-03-06 2019-03-06 心血管リスクを低減するためのpcsk9阻害剤の使用
JP2023207363A Pending JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023207363A Pending JP2024028919A (ja) 2018-03-06 2023-12-08 心血管リスクを低減するためのpcsk9阻害剤の使用

Country Status (12)

Country Link
US (1) US20190292273A1 (cg-RX-API-DMAC7.html)
EP (1) EP3762026B1 (cg-RX-API-DMAC7.html)
JP (2) JP7426940B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200129127A (cg-RX-API-DMAC7.html)
CN (1) CN113015543A (cg-RX-API-DMAC7.html)
AU (1) AU2019231703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3092936A1 (cg-RX-API-DMAC7.html)
ES (1) ES3072854T3 (cg-RX-API-DMAC7.html)
IL (1) IL277127B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020009246A (cg-RX-API-DMAC7.html)
TW (2) TWI924621B (cg-RX-API-DMAC7.html)
WO (1) WO2019173530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
ES2683943T3 (es) 2010-10-22 2018-09-28 Neuravi Limited Sistema de captura y extirpación de coágulos
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
US12076037B2 (en) 2011-03-09 2024-09-03 Neuravi Limited Systems and methods to restore perfusion to a vessel
ES3029850T3 (en) 2011-03-09 2025-06-25 Neuravi Ltd A clot retrieval device for removing occlusive clot from a blood vessel
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EP2967610B1 (en) 2013-03-14 2018-12-05 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
US10201360B2 (en) 2013-03-14 2019-02-12 Neuravi Limited Devices and methods for removal of acute blockages from blood vessels
US9433429B2 (en) 2013-03-14 2016-09-06 Neuravi Limited Clot retrieval devices
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
CN106999196B (zh) 2014-11-26 2020-07-28 尼尔拉维有限公司 从血管除去阻塞性血栓的取血栓装置
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
US10617435B2 (en) 2014-11-26 2020-04-14 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
WO2018046408A2 (en) 2016-09-06 2018-03-15 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
JP2022548950A (ja) * 2019-09-19 2022-11-22 イノベント バイオロジクス(スーチョウ)カンパニー,リミティド 抗pcsk9抗体を利用したコレステロール関連疾患の予防または治療方法
US11712231B2 (en) 2019-10-29 2023-08-01 Neuravi Limited Proximal locking assembly design for dual stent mechanical thrombectomy device
US11517340B2 (en) 2019-12-03 2022-12-06 Neuravi Limited Stentriever devices for removing an occlusive clot from a vessel and methods thereof
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11717308B2 (en) 2020-04-17 2023-08-08 Neuravi Limited Clot retrieval device for removing heterogeneous clots from a blood vessel
US11730501B2 (en) 2020-04-17 2023-08-22 Neuravi Limited Floating clot retrieval device for removing clots from a blood vessel
US11737771B2 (en) 2020-06-18 2023-08-29 Neuravi Limited Dual channel thrombectomy device
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11864781B2 (en) 2020-09-23 2024-01-09 Neuravi Limited Rotating frame thrombectomy device
US11937837B2 (en) 2020-12-29 2024-03-26 Neuravi Limited Fibrin rich / soft clot mechanical thrombectomy device
US12029442B2 (en) 2021-01-14 2024-07-09 Neuravi Limited Systems and methods for a dual elongated member clot retrieval apparatus
US12064130B2 (en) 2021-03-18 2024-08-20 Neuravi Limited Vascular obstruction retrieval device having sliding cages pinch mechanism
US11974764B2 (en) 2021-06-04 2024-05-07 Neuravi Limited Self-orienting rotating stentriever pinching cells
CN115413625A (zh) * 2022-08-22 2022-12-02 郑咏秋 一种类风湿性冠心病动物模型及其构建方法和应用
CN118116596B (zh) * 2024-04-25 2024-07-02 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN121015868B (zh) * 2025-10-29 2026-03-20 核工业四一六医院 Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508142A (ja) 2011-01-28 2014-04-03 サノフイ Pcsk9に対するヒト抗体を含んでなる医薬組成物
JP2014527967A (ja) 2011-09-16 2014-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. プロタンパク質転換酵素サブチリシンケキシン−9(PCSK9)の阻害剤を投与することによってリポタンパク質(a)レベルを低下させる方法
JP2017509624A (ja) 2014-03-17 2017-04-06 サノフィ・バイオテクノロジー 心血管リスクを低減させる方法
JP2017522316A (ja) 2014-07-16 2017-08-10 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9603826B2 (en) * 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
MX373298B (es) * 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201890519A1 (ru) * 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508142A (ja) 2011-01-28 2014-04-03 サノフイ Pcsk9に対するヒト抗体を含んでなる医薬組成物
JP2014527967A (ja) 2011-09-16 2014-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. プロタンパク質転換酵素サブチリシンケキシン−9(PCSK9)の阻害剤を投与することによってリポタンパク質(a)レベルを低下させる方法
JP2017509624A (ja) 2014-03-17 2017-04-06 サノフィ・バイオテクノロジー 心血管リスクを低減させる方法
JP2017522316A (ja) 2014-07-16 2017-08-10 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Circulation,2016年,Vol. 134,pp. 1931-1943
Lancet,2017年,Vol. 390,pp. 1962-1971
ODYSSEY LONG TERM,https://www.wikijournalclub.org/wiki/ODYSSEY_LONG_TERM
The New England Journal of Medicine,2015年,Vol. 372, No. 16,pp. 1489-1499

Also Published As

Publication number Publication date
ES3072854T3 (en) 2026-07-06
TW201945401A (zh) 2019-12-01
WO2019173530A1 (en) 2019-09-12
JP2021515772A (ja) 2021-06-24
MX2020009246A (es) 2021-01-15
AU2019231703A1 (en) 2020-10-22
IL277127B2 (en) 2025-11-01
IL277127B1 (en) 2025-07-01
CN113015543A (zh) 2021-06-22
KR20200129127A (ko) 2020-11-17
IL277127A (en) 2020-10-29
JP2024028919A (ja) 2024-03-05
TWI924621B (zh) 2026-05-11
US20190292273A1 (en) 2019-09-26
EP3762026B1 (en) 2026-04-08
TW202521589A (zh) 2025-06-01
EP3762026C0 (en) 2026-04-08
EP3762026A1 (en) 2021-01-13
CA3092936A1 (en) 2019-09-12
RU2020132463A (ru) 2022-04-06

Similar Documents

Publication Publication Date Title
JP2024028919A (ja) 心血管リスクを低減するためのpcsk9阻害剤の使用
US20220144969A1 (en) Methods for reducing cardiovascular risk
US20240261400A1 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
JP6912374B2 (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
JP2019512472A (ja) Angptl3阻害剤と組み合わせてpcsk9阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのpcsk9阻害剤の使用
JP2020143156A (ja) 心血管リスクを低減させる方法
RU2837845C2 (ru) Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска
JP7104108B2 (ja) ヘテロ接合性家族性高コレステロール血症(heFH)を有する患者を処置するための方法
HK40114248A (en) Methods for reducing cardiovascular risk

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240123

R150 Certificate of patent or registration of utility model

Ref document number: 7426940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150